Bibliographic Details
| Title: |
BIFIDOBACTERIUM LONGUM AND HIPPOCAMPAL BDNF EXPRESSION |
| Document Number: |
20110280837 |
| Publication Date: |
November 17, 2011 |
| Appl. No: |
12/937866 |
| Application Filed: |
April 08, 2009 |
| Abstract: |
The present invention relates in general to edible compositions comprising probiotics. One embodiment of the present invention relates to an edible composition comprising Bifidobacterium longum ATCC BAA-999. This composition can be used to attenuate reductions in hippocampal BDNF expression and/or to treat or prevent anxiety and related disorders. |
| Inventors: |
Bergonzelli, Gabriela (Bussigny, CH); Ornstein, Kurt (Savigny, CH); Cherbut, Christine (Pully, CH) |
| Assignees: |
NESTEC S.A. (Vevey, CH) |
| Claim: |
1. Edible composition comprising Bifidobacterium longum ATCC BAA-999. |
| Claim: |
2. Composition in accordance with claim 1, wherein the composition is a food composition, a pet food composition, a dietary supplement, a drink, and/or medical composition. |
| Claim: |
3. Composition in accordance with one of claims 1-2, wherein the composition comprises additionally at least one other kind of other food grade bacteria, wherein the food grade bacteria are preferably selected from the group consisting of lactic acid bacteria, bifidobacteria, propionibacteria or mixtures thereof. |
| Claim: |
4. Composition in accordance with one of claims 1-3, wherein the composition further contains at least one prebiotic. |
| Claim: |
5. Composition in accordance with claim 4, wherein the prebiotic is selected from the group consisting of oligosaccharides and optionally contain fructose, galactose, mannose, soy and/or inulin; dietary fibers; or mixtures thereof. |
| Claim: |
6. Composition in accordance with one of claims 1-5, wherein at least a part of the Bifidobacterium longum ATCC BAA-999, are alive in the composition. |
| Claim: |
7. Composition in accordance with one of claims 1-5, wherein at least a part of the Bifidobacterium longum ATCC BAA-999, are not alive in the composition. |
| Claim: |
8. Composition in accordance with one of claims 1-7, wherein composition comprises between 104 and 1010 non-replicating cells of Bifidobacterium longum ATCC BAA-999, per daily dose. |
| Claim: |
9. Composition in accordance with one of claims 1-7, wherein composition comprises between 102 and 108 non-replicating cells of Bifidobacterium longum ATCC BAA-999, per g of the dry weight of the composition. |
| Claim: |
10. Composition in accordance with claims 1-9 for increasing hippocampal BDNF expression. |
| Claim: |
11. Composition in accordance with claim 10 for treating or preventing anxiety and/or anxiety related disorders. |
| Claim: |
12. Composition in accordance with claim 10 for treating or preventing neurodegenerative diseases. |
| Claim: |
13. Composition in accordance with claim 11 wherein the anxiety related disorder is selected from the group consisting of depression, abuse of substances, such as alcohol abuse, cocaine abuse, opiate abuse, compulsive eating, and deleterious effects of stress such as sleep disturbances and cognitive impairments. |
| Claim: |
14. Composition in accordance with claim 12, wherein the neurodegenerative diseases are selected from the group consisting of Alzheimer's, Parkinson's, Huntington's disease, brain inflammation and diabetes. |
| Claim: |
15. Composition in accordance with claim 12 for improving brain performance, in particular in aging. |
| Current U.S. Class: |
424/933 |
| Current International Class: |
61; 61; 61; 61; 23; 61; 61; 23; 23; 23; 61; 61 |
| Accession Number: |
edspap.20110280837 |
| Database: |
USPTO Patent Applications |
